血清乳铁蛋白在脓毒症近期预后评估中的作用
摘要
间入院的 40 例脓毒症患者和同期健康者 40 人为对照组，根据脓毒症 3.0 诊断标准选择脓毒症患者，依据 30 天生存情
况分为生存组和死亡组 , 并采用 ELISA 法测定血清中 LF 水平，比较两组血清 LF 的差异。结果 ：与对照组比较 , 脓毒症
生 存 组、 脓 毒 症 死 亡 组 血 清 LF 均 明 显 升 高 [μg/mL:710.476（598.7499，805.086）vs.948.942（859.339，1022.316），
1062.290(975.902,1145.964)，P <0.001]; 与生存组比较 , 死亡组血清 LF 明显升高 [μg/mL:1062.290(975.902,1145.964）
vs.948.942（859.339，1022.316）,P = 0.002]。ROC 曲线分析显示 , 血清 LF 对脓毒症预后的曲线下面积为 0.762，截断值为
955.534 μg / mL，此时敏感度 0.913、特异度 0.588。Cox 回归分析显示 , 血清 LF 为脓毒症近期预后危险因素 (HR = 1.01,P
= 0.0018)。生存曲线分析生存分析显示 , 血清 LF > 955.534 μg / mL 脓毒症患者 30d 病死率高于血清 LF < 955.534 μg /
mL 的脓毒症患者 (P <0.05)。结论 ：随着 LF 的升高，脓毒症患者近期预后的死亡率也越高。
关键词
全文:
PDF参考
[1] Singer M, Deutschman CS, Seymour CW, et al.
The Third International Consensus Definitions for Sepsis
and Septic Shock (Sepsis-3). JAMA. 2016,315(8): 801-810.
[2] Cecconi M, Evans L, Levy M, et al. Sepsis and
septic shock. Lancet. 2018;392(10141):75-87.
[3] Yu MH, Chen MH, Han F, et al. Prognostic value
of the biomarkers serum amyloid A and nitric oxide in
patients with sepsis. Int Immunopharmacol. 2018;62:287-
292.
[4] Rudd KE, Johnson SC, Agesa KM, et al. Global,
regional, and national sepsis incidence and mortality,
1990-2017: analysis for the Global Burden of Disease
Study. Lancet. 2020;395(10219):200-211.
[5] Duggan S, Leonhardt I, Hunniger K, et al. Host
response to Candida albicans bloodstream infection and
sepsis, Virulence 2015;6(4):316–326.
[6] Meynaar IA, Droog W, Batstra M, et al. In
critically ill patients, serum procalcitonin is more useful in
differentiating between sepsis and SIRS than CRP, Il-6, or
LBP. Crit Care Res Pract. 2011;2011:594645.
[7] Huson MA, Kalkman R, Hoogendijk AJ, et al.
Impact of HIV infection on the haemostatic response during
sepsis and ma-laria, Br. J. Haematol. 2016;173(6):918–926.
[8] McHugh L, Seldon TA, Brandon RA, et al. A
molecular host response assay to discriminate between sepsis
and infection-negative systemic inflammation in critically
ill patients: discovery and validation in independent cohorts,
PLoS Med. 2015;12(12): e1001916.
[9] Decembrino L, DeAmici M, De Silvestri A, et al.
Plasma lactoferrin levels in newborn preterm infants with
sepsis. J Matern Fetal Neonatal Med. 2017;30(23):2890-
2893.
[10] Lepanto MS, Rosa L, Paesano R, et al.
Lactoferrin in Aseptic and Septic Inflammation. Molecules.
2019;24(7):1323.
[11] Sortino O, Hullsiek KH, Richards E, et al. The
Effects of Recombinant Human Lactoferrin on Immune
Activation and the Intestinal Microbiome Among Persons
Living with Human Immunodeficiency Virus and Receiving
Antiretroviral Therapy. J Infect Dis. 2019;219(12):1963-
1968.
[12] Ahmed AM, Mohammed AT, et al.. Serum
Biomarkers for the Early Detection of the EarlyOnset Neonatal Sepsis. Advances in Neonatal Care.
2019;19(5):E26–E32.
[13]Berkestedt I, Herwald H, Ljunggren L, et al.
Elevated plasma levels of antimicrobial polypeptides in
patients with severe sepsis. J Innate Immun 2010;2:478–
482.
[14] Drago-Serrano ME, Campos-Rodríguez R,
Carrero JC, et al. Lactoferrin: Balancing Ups and Downs of
Inflammation Due to Microbial Infections. Int J Mol Sci.
2017;18(3):501.
[15] Okubo K, Kamiya M, Urano Y, et al. Lactoferrin
Suppresses Neutrophil Extracellular Traps Release in
Inflammation. EBioMedicine. 2016;10:204-215.
[16] Hu P, Zong Q, Zhao Y, et al. Lactoferrin
Attenuates Intestinal Barrier Dysfunction and Inflammation
By Modulating the MAPK Pathway and Gut Microbes in
Mice. J Nutr. 2022:nxac200.
[17]Thomas NJ, Carcillo JA, Doughty LA, et al. Plasma
concentrations of defensins and lactoferrin in children with
severe sepsis. Pediatr Infect Dis J. 2002;21(1):34-38.
[18]Rowe TA, McKoy JM. Sepsis in Older Adults.
Infect Dis Clin North Am. 2017;31(4):731-742.
Refbacks
- 当前没有refback。
